{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"FEED","limit":50},"count":50,"signals":[{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":15,"context":"am and played a central role in identifying market opportunities, building clinical and commercial strategy, and positioning superDimension as a leader in navigational bronchoscopy. In 2012, Covidien acquired superDimension for approximately $300 million. Throughout his career, Dr. Besser has focused on identifying breakthrough technologies and developing them through every stage of product development - from concept and regulatory clearan","filed_date":"2025-11-10","accession":"0001493152-25-021353","full_text":"https://origin.rootz.global/static/filing/0001493152-25-021353.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":28,"context":"Date shall have the meaning ascribed to such term in Section 4.1(c). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Maximum Rate shall have the meaning ascribed to such t","filed_date":"2025-07-22","accession":"0001641172-25-020569","full_text":"https://origin.rootz.global/static/filing/0001641172-25-020569.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":105,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third -party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. **UroShield.**If cleared or approved by the FDA for the U.S. market, we expect these products to be used in inpatient settings and therefor","filed_date":"2025-03-31","accession":"0001641172-25-001613","full_text":"https://origin.rootz.global/static/filing/0001641172-25-001613.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":21,"context":"nimally-invasive pulmonology devices. Dr. Besser helped lead superDimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for approximately $300 million. As a seasoned entrepreneur, Dr. Besser specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international sales an","filed_date":"2025-03-31","accession":"0001641172-25-001613","full_text":"https://origin.rootz.global/static/filing/0001641172-25-001613.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":71,"context":"investment decision, to assess whether the net proceeds are being used appropriately. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our securities to decline and delay the development of our product candidates. Pending the application of these funds, we may invest the net proceeds from this off","filed_date":"2025-02-14","accession":"0001493152-25-006878","full_text":"https://origin.rootz.global/static/filing/0001493152-25-006878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":23,"context":"nimally-invasive pulmonology devices. Dr. Besser helped lead superDimension from its inception, serving on the core team that identified opportunities within the pulmonology market. In 2012, Covidien acquired superDimension for approximately $300 million. As a seasoned entrepreneur, Dr. Besser specializes in identifying breakthrough technologies and developing them throughout all product development phases, including international sales an","filed_date":"2025-02-14","accession":"0001493152-25-006878","full_text":"https://origin.rootz.global/static/filing/0001493152-25-006878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":24,"context":"s, a Fortune 250 retail Oil and Gas company. Prior to that, she served as Vice President and Treasurer & Head of Tax at Kinetic Concepts, Inc. (KCI) a $1.5 billion MedTech company, which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number of strategic transactions, including two leveraged buyouts and an initial public offering. Ms. Schroeder began her career at Ernst & Whinney before","filed_date":"2024-10-29","accession":"0001493152-24-042890","full_text":"https://origin.rootz.global/static/filing/0001493152-24-042890.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":62,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third -party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. | 26 | | **** **UroShield.**If cleared or approved by the FDA for the U.S. market, we expect these products to be used in inpatient setting","filed_date":"2024-04-08","accession":"0001493152-24-013966","full_text":"https://origin.rootz.global/static/filing/0001493152-24-013966.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":24,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third -party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. | 27 | | **** **UroShield.**If cleared or approved by the FDA for the U.S. market, we expect these products to be used in inpatient setting","filed_date":"2023-04-17","accession":"0001493152-23-012570","full_text":"https://origin.rootz.global/static/filing/0001493152-23-012570.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":14,"context":"s, a Fortune 250 retail Oil and Gas company. Prior to that, she served as Vice President and Treasurer & Head of Tax at Kinetic Concepts, Inc. (KCI) a $1.5 billion MedTech company, which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number of strategic transactions, including two leveraged buyouts and an initial public offering. Ms. Schroeder began her career at Ernst & Whinney before","filed_date":"2022-10-31","accession":"0001493152-22-029915","full_text":"https://origin.rootz.global/static/filing/0001493152-22-029915.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":13,"context":"s, a Fortune 250 retail Oil and Gas company. Prior to that, she served as Vice President and Treasurer & Head of Tax at Kinetic Concepts, Inc. (KCI) a $1.5 billion MedTech company, which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number of strategic transactions, including two leveraged buyouts and an initial public offering. Ms. Schroeder began her career at Ernst & Whinney before","filed_date":"2022-07-26","accession":"0001493152-22-020338","full_text":"https://origin.rootz.global/static/filing/0001493152-22-020338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":21,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third -party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. | 25 | | **** **UroShield.**We expect these products to be used in inpatient settings and therefore reimbursed under the Diagnosis Related","filed_date":"2022-04-15","accession":"0001493152-22-009985","full_text":"https://origin.rootz.global/static/filing/0001493152-22-009985.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":100,"match_count":29,"context":"f Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021. | | |  |  | | |  (3) |  Approval, on an advisory basis, of the compensation paid to our named executive officers. | | |  |  | | |  (4) |  Approval, on an advisory basis, of the frequency of future advisory votes on the compensation paid to our named executive officers. | | |  |  | | |  (5) |  Such other busine","filed_date":"2021-04-30","accession":"0001493152-21-010176","full_text":"https://origin.rootz.global/static/filing/0001493152-21-010176.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":21,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third -party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. | 25 | | **UroShield.**We expect these products to be used in inpatient settings and therefore reimbursed under the Diagnosis Related Group","filed_date":"2021-04-15","accession":"0001493152-21-008951","full_text":"https://origin.rootz.global/static/filing/0001493152-21-008951.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":25,"context":"cts, may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. Assessment of the complete extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new inform","filed_date":"2020-11-16","accession":"0001493152-20-021695","full_text":"https://origin.rootz.global/static/filing/0001493152-20-021695.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":30,"context":"cts, may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. Assessment of the complete extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new inform","filed_date":"2020-08-24","accession":"0001493152-20-016624","full_text":"https://origin.rootz.global/static/filing/0001493152-20-016624.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":29,"context":"cts, may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. Assessment of the complete extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new inform","filed_date":"2020-08-19","accession":"0001493152-20-016309","full_text":"https://origin.rootz.global/static/filing/0001493152-20-016309.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":32,"context":"cts, may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. The extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge","filed_date":"2020-07-06","accession":"0001493152-20-012689","full_text":"https://origin.rootz.global/static/filing/0001493152-20-012689.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":20,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. **UroShield.**We expect these products to be used in inpatient settings and therefore reimbursed under the DRG or per diem reimbursement sy","filed_date":"2020-05-20","accession":"0001493152-20-009519","full_text":"https://origin.rootz.global/static/filing/0001493152-20-009519.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":10,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. **UroShield.**We expect these products to be used in inpatient settings and therefore reimbursed under the DRG or per diem reimbursement sy","filed_date":"2019-04-15","accession":"0001615774-19-005785","full_text":"https://origin.rootz.global/static/filing/0001615774-19-005785.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":10,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. **UroShield.** We expect these products to be used in inpatient settings and therefore reimbursed under the DRG or per diem reimbursement s","filed_date":"2018-03-29","accession":"0001615774-18-002203","full_text":"https://origin.rootz.global/static/filing/0001615774-18-002203.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":6,"context":"tive action. There can be no assurance that we will not be required to incur significant costs to comply with such laws and regulations in the future, or that such laws or regulations will not have a material adverse effect upon our business. **We are uncertain regarding the success of our clinical trials for our products in development.** We believe that all of our products in development, which consist of LungShield a","filed_date":"2017-08-14","accession":"0001615774-17-004390","full_text":"https://origin.rootz.global/static/filing/0001615774-17-004390.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":10,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. The Diagnosis Related Group System, or DRG, is the system of reimbursement that is used in the United States for hospitalized patients as w","filed_date":"2017-03-31","accession":"0001144204-17-018057","full_text":"https://origin.rootz.global/static/filing/0001144204-17-018057.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":8,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. The Diagnosis Related Group System, or DRG, is the system of reimbursement that is used in the United States for hospitalized patients as w","filed_date":"2016-03-30","accession":"0001144204-16-091141","full_text":"https://origin.rootz.global/static/filing/0001144204-16-091141.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":9,"context":"adversely affect the demand for our products or our ability to sell these products on a profitable basis. The unavailability or inadequacy of third party payer coverage or reimbursement would have a material adverse effect on our business, operating results and financial condition. The Diagnosis Related Group System, or DRG, is the system of reimbursement that is used in the United States for hospitalized patients as w","filed_date":"2015-03-30","accession":"0001144204-15-019323","full_text":"https://origin.rootz.global/static/filing/0001144204-15-019323.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":100,"match_count":44,"context":"usinesses as described in the Commission Documents, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, shareholders e","filed_date":"2026-08-12","accession":"0001493152-26-037254","full_text":"https://origin.rootz.global/static/filing/0001493152-26-037254.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":88,"match_count":11,"context":"NVEH Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (Second Merger Sub), and Predecessor ENvue, the Company and Predecessor ENvue effected (i) a merger of First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist and Predecessor ENvue becoming a wholly-owned subsidiary the Company and (ii) the merger of Predecessor EN","filed_date":"2025-05-20","accession":"0001641172-25-011788","full_text":"https://origin.rootz.global/static/filing/0001641172-25-011788.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":88,"match_count":11,"context":"mmon stock as of November 29, 2023 by: |  |  each person known by us to beneficially own more than 5.0% of our common stock; | | |  |  | | |  |  each of our directors; | | |  |  | | |  |  each of the Named Executive Officers; and | | |  |  | | |  |  all of our directors and executive officers as a group. | | The percentages of common stock beneficially owned are reported on the basis of regulations of the SEC governing","filed_date":"2023-11-30","accession":"0001493152-23-043119","full_text":"https://origin.rootz.global/static/filing/0001493152-23-043119.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":88,"match_count":11,"context":"s, a Fortune 250 retail Oil and Gas company. Prior to that, she served as Vice President and Treasurer & Head of Tax at Kinetic Concepts, Inc. (KCI) a $1.5 billion MedTech company, which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number of strategic transactions, including two leveraged buyouts and an initial public offering. Ms. Schroeder began her career at Ernst & Whinney before","filed_date":"2023-05-01","accession":"0001493152-23-015001","full_text":"https://origin.rootz.global/static/filing/0001493152-23-015001.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":83,"match_count":6,"context":"commercial profitability. If the Company is unable to obtain additional financing, the development of its product candidates and the Companys commercial strategy may be impacted and there could be a material adverse effect on the Companys business and financial condition. These financial statements do not include any adjustments that may result from the outcome of this uncertainty. *Other Uncertainties* On May 23, 2023","filed_date":"2023-11-13","accession":"0001493152-23-040577","full_text":"https://origin.rootz.global/static/filing/0001493152-23-040577.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"owing such termination/separation. Upon the expiration of the applicable deferral period, any payments which would have otherwise been made during that period (whether in a single lump sum or in installments) in the absence of this Article III shall be paid to the Executive or the Executives beneficiary in one lump sum, plus interest thereon, at the Delayed Payment Interest Rate (as defined below) co","filed_date":"2024-09-25","accession":"0001493152-24-038139","full_text":"https://origin.rootz.global/static/filing/0001493152-24-038139.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":79,"match_count":8,"context":"ed liability company and a wholly-owned subsidiary of the Company (Second Merger Sub), and ENvue Medical Holdings, Corp. (Predecessor ENvue or ENvue), the Company and Predecessor ENvue effected (i) a merger of First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist and Predecessor ENvue becoming a wholly-owned subsidiary the Company and (ii) the merger of Predecessor EN","filed_date":"2025-05-14","accession":"0001641172-25-010173","full_text":"https://origin.rootz.global/static/filing/0001641172-25-010173.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":78,"match_count":6,"context":"commercial profitability. If the Company is unable to obtain additional financing, the development of its product candidates and the Companys commercial strategy may be impacted and there could be a material adverse effect on the Companys business and financial condition. These financial statements do not include any adjustments that may result from the outcome of this uncertainty. **NOTE 3 SUMMARY OF SIGNIFICANT ACCOU","filed_date":"2024-11-14","accession":"0001493152-24-045726","full_text":"https://origin.rootz.global/static/filing/0001493152-24-045726.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":78,"match_count":6,"context":"commercial profitability. If the Company is unable to obtain additional financing, the development of its product candidates and the Companys commercial strategy may be impacted and there could be a material adverse effect on the Companys business and financial condition. These financial statements do not include any adjustments that may result from the outcome of this uncertainty. **NOTE 3 SUMMARY OF SIGNIFICANT ACCOU","filed_date":"2024-08-14","accession":"0001493152-24-032138","full_text":"https://origin.rootz.global/static/filing/0001493152-24-032138.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":78,"match_count":6,"context":"commercial profitability. If the Company is unable to obtain additional financing, the development of its product candidates and the Companys commercial strategy may be impacted and there could be a material adverse effect on the Companys business and financial condition. These financial statements do not include any adjustments that may result from the outcome of this uncertainty. **NOTE 3 SUMMARY OF SIGNIFICANT ACCOU","filed_date":"2024-05-15","accession":"0001493152-24-019675","full_text":"https://origin.rootz.global/static/filing/0001493152-24-019675.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":72,"match_count":9,"context":"ry of the Company (Second Merger Sub), and Predecessor ENvue Medical Holdings LLC (previously: Envizion Medical Holding Corp. hereinafter: ENvue****), the Company and Predecessor ENvue effected (i) a merger of First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist and Predecessor ENvue becoming a wholly-owned subsidiary the Company and (ii) the merger of Predecessor EN","filed_date":"2025-11-14","accession":"0001493152-25-023542","full_text":"https://origin.rootz.global/static/filing/0001493152-25-023542.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":72,"match_count":9,"context":"NVEH Merger Sub II, LLC, a Delaware limited liability company and a wholly-owned subsidiary of the Company (Second Merger Sub), and Predecessor ENvue, the Company and Predecessor ENvue effected (i) a merger of First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist and Predecessor ENvue becoming a wholly-owned subsidiary the Company and (ii) the merger of Predecessor EN","filed_date":"2025-08-19","accession":"0001641172-25-024854","full_text":"https://origin.rootz.global/static/filing/0001641172-25-024854.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":72,"match_count":9,"context":"r management, finance and consulting experience. **Required Vote and Board Recommendation** If a quorum is present and voting, the seven Company Nominees receiving the highest number of votes will be elected as directors. If you hold your shares in your own name and abstain from voting on the election of directors, your abstention will have no effect on the vote. If you hold your shares through a broker and you do n","filed_date":"2018-04-30","accession":"0001615774-18-003083","full_text":"https://origin.rootz.global/static/filing/0001615774-18-003083.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"platform_shift","strength":68,"match_count":1,"context":"s to comply with applicable regulations. If we do not adequately address problems associated with our devices, we may face additional regulatory requirements or enforcement action, including required new marketing authorizations, FDA warning letters, product seizure, injunctions, administrative penalties, or civil or criminal proceedings. We may initiate voluntary withdrawals, removals, or corrections for o","filed_date":"2025-02-14","accession":"0001493152-25-006878","full_text":"https://origin.rootz.global/static/filing/0001493152-25-006878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":64,"match_count":8,"context":"s, a Fortune 250 retail Oil and Gas company. Prior to that, she served as Vice President and Treasurer & Head of Tax at Kinetic Concepts, Inc. (KCI) a $1.5 billion MedTech company, which was recently purchased by 3M for $6.7 billion. At KCI, she held key roles in a number of strategic transactions, including two leveraged buyouts and an initial public offering. Ms. Schroeder began her career at Ernst & Whinney before","filed_date":"2024-04-26","accession":"0001493152-24-016463","full_text":"https://origin.rootz.global/static/filing/0001493152-24-016463.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":64,"match_count":8,"context":"ior management, finance and consulting experience. **Required Vote and Board Recommendation** If a quorum is present and voting, the six Company Nominees receiving the highest number of votes will be elected as directors. If you hold your shares in your own name and abstain from voting on the election of directors, your abstention will have no effect on the vote. If you hold your shares through a broker and you do n","filed_date":"2020-06-15","accession":"0001493152-20-011173","full_text":"https://origin.rootz.global/static/filing/0001493152-20-011173.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"strategic_event","strength":64,"match_count":8,"context":"ior management, finance and consulting experience. **Required Vote and Board Recommendation** If a quorum is present and voting, the six Company Nominees receiving the highest number of votes will be elected as directors. If you hold your shares in your own name and abstain from voting on the election of directors, your abstention will have no effect on the vote. If you hold your shares through a broker and you do n","filed_date":"2019-04-30","accession":"0001615774-19-006754","full_text":"https://origin.rootz.global/static/filing/0001615774-19-006754.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":62,"match_count":4,"context":"cts, may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. Assessment of the complete extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new inform","filed_date":"2021-08-16","accession":"0001493152-21-020074","full_text":"https://origin.rootz.global/static/filing/0001493152-21-020074.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":61,"match_count":7,"context":"e sale of our products. For example, the Patient Protection and Affordable Act of 2010, commonly referred to as the Affordable Care Act, contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new progr","filed_date":"2025-02-14","accession":"0001493152-25-006878","full_text":"https://origin.rootz.global/static/filing/0001493152-25-006878.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":59,"match_count":3,"context":"nomies of those countries generally. If the United States or other countries where we operate experience substantial inflation in the future, our business may be adversely affected. This could have a material adverse effect on our business, financial condition, results of operations, or cash flows. Specifically, our existing distributor agreements limit the amount that we can increase the price that we sell our products","filed_date":"2022-11-14","accession":"0001493152-22-032176","full_text":"https://origin.rootz.global/static/filing/0001493152-22-032176.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":57,"match_count":4,"context":"investment decision, to assess whether the net proceeds are being used appropriately. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our securities to decline and delay the development of our product candidates. Pending the application of these funds, we may invest the net proceeds from this off","filed_date":"2025-05-14","accession":"0001641172-25-010173","full_text":"https://origin.rootz.global/static/filing/0001641172-25-010173.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"ai_adoption","strength":56,"match_count":7,"context":".S. Centers for Medicare and Medicaid Services (CMS) approved our PainShield for reimbursement for Medicare beneficiaries on a national basis. We were notified on March 30, 2020 that our Medicare Enrollment Application was approved, and we are now an approved Medicare Supplier for Durable Medical Equipment, or DME, through the National Supplier Clearinghouse, Palmetto-GBA as well as Noridian Administ","filed_date":"2021-04-15","accession":"0001493152-21-008951","full_text":"https://origin.rootz.global/static/filing/0001493152-21-008951.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":54,"match_count":3,"context":"cts, may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. Assessment of the complete extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new inform","filed_date":"2021-11-15","accession":"0001493152-21-028715","full_text":"https://origin.rootz.global/static/filing/0001493152-21-028715.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"nomies of those countries generally. If the United States or other countries where we operate experience substantial inflation in the future, our business may be adversely affected. This could have a material adverse effect on our business, financial condition, results of operations, or cash flows. Specifically, our existing distributor agreements limit the amount that we can increase the price that we sell our products","filed_date":"2022-08-15","accession":"0001493152-22-023047","full_text":"https://origin.rootz.global/static/filing/0001493152-22-023047.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"FEED","company":"ENvue Medical, Inc.","exchange":"Nasdaq","sector":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","signal_type":"risk_factor","strength":49,"match_count":3,"context":"cts, may continue to affect our operation, may further divert the attention and efforts of the medical community to coping with COVID-19 and disrupt the marketplace in which we operate and may have a material adverse effect on our operations. Assessment of the complete extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new inform","filed_date":"2021-05-24","accession":"0001493152-21-012734","full_text":"https://origin.rootz.global/static/filing/0001493152-21-012734.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"a37e61bc171d910e9f70ce8f78e33952f2e8032f401f2515254234f9bc40088c","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"cd30b494bfb1bd2b4233f826fc1453d5891cbbbffdbc7b04a865ac1a82ce6d91","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":18,"hourly_limit":500,"remaining":482,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}